Multicenter patch testing with methylchloroisothizoline/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Multicenter patch testing with methylchloroisothizoline/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group. / Engfeldt, Malin; Ale, Iris; Andersen, Klaus E.; Elsner, Peter; Goh, Chee Leok; Goossens, An; Jerajani, Hemangi; Matsunaga, Kayoko; Bruze, Magnus.

I: Dermatitis, Vol. 28, Nr. 3, 2017, s. 215-218.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Engfeldt, Malin ; Ale, Iris ; Andersen, Klaus E. ; Elsner, Peter ; Goh, Chee Leok ; Goossens, An ; Jerajani, Hemangi ; Matsunaga, Kayoko ; Bruze, Magnus. / Multicenter patch testing with methylchloroisothizoline/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group. I: Dermatitis. 2017 ; Vol. 28, Nr. 3. s. 215-218.

RIS

TY - JOUR

T1 - Multicenter patch testing with methylchloroisothizoline/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group

AU - Engfeldt, Malin

AU - Ale, Iris

AU - Andersen, Klaus E.

AU - Elsner, Peter

AU - Goh, Chee Leok

AU - Goossens, An

AU - Jerajani, Hemangi

AU - Matsunaga, Kayoko

AU - Bruze, Magnus

PY - 2017

Y1 - 2017

N2 - Background: The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. Objectives: The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. Patients and Methods: Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series. Results: Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P G 0.001). Conclusions: Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 Kg/cm2) diagnoses significantly more contact allergy than 0.01% (dose, 3 Kg/cm2), without resulting in more adverse reactions.Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series.

AB - Background: The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. Objectives: The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. Patients and Methods: Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series. Results: Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P G 0.001). Conclusions: Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 Kg/cm2) diagnoses significantly more contact allergy than 0.01% (dose, 3 Kg/cm2), without resulting in more adverse reactions.Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series.

UR - http://www.scopus.com/inward/record.url?scp=85021076977&partnerID=8YFLogxK

U2 - 10.1097/DER.0000000000000287

DO - 10.1097/DER.0000000000000287

M3 - Article

C2 - 28509716

AN - SCOPUS:85021076977

VL - 28

SP - 215

EP - 218

JO - Dermatitis

JF - Dermatitis

SN - 1710-3568

IS - 3

ER -